Improved pharmacokinetics of AMG 517 through co-crystallization part 2: analysis of 12 carboxylic acid co-crystals.
暂无分享,去创建一个
Matthew L Peterson | M. Peterson | E. Munson | Jonathan Roberts | Mary K. Stanton | Eric J Munson | Ron C Kelly | Mary C Wells | Mary K Stanton | Adria Colletti | Meghan Langley | John Roberts | Mary Wells | A. Colletti | M. Langley | R. Kelly
[1] A. Cheng,et al. Preparation, solid state characterization, and single crystal structure analysis of N-(4-(6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yloxy)benzo[d]thiazol-2-yl)acetamide crystal forms , 2011 .
[2] J. C. Price,et al. Accelerated Dissolution Testing for Controlled Release Microspheres Using the Flow-Through Dissolution Apparatus , 2009, Pharmaceutical development and technology.
[3] A. Bak,et al. Physicochemical Properties of Pharmaceutical Co-Crystals: A Case Study of Ten AMG 517 Co-Crystals , 2008 .
[4] Michael J Zaworotko,et al. Expanding the scope of crystal form evaluation in pharmaceutical science. , 2006, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[5] L. Lesko,et al. The Relative Bioavailability and In Vivo-In Vitro Correlations for Four Marketed Carbamazepine Tablets , 1998, Pharmaceutical Research.
[6] Miranda L. Cheney,et al. Effects of Crystal Form on Solubility and Pharmacokinetics: A Crystal Engineering Case Study of Lamotrigine , 2010 .
[7] Christos Reppas,et al. Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms , 2004, Pharmaceutical Research.
[8] Matthew L Peterson,et al. Improved pharmacokinetics of AMG 517 through co-crystallization. Part 1: comparison of two acids with corresponding amide co-crystals. , 2010, Journal of pharmaceutical sciences.
[9] V. Saxena,et al. Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates. , 2009, Journal of pharmaceutical sciences.
[10] C A Hirsch,et al. Fenoprofen: drug form selection and preformulation stability studies. , 1978, Journal of pharmaceutical sciences.
[11] Kenneth R. Morris,et al. An integrated approach to the selection of optimal salt form for a new drug candidate , 1994 .
[12] N. Chen,et al. Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate. , 2007, Journal of medicinal chemistry.
[13] Tim Morris,et al. Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.
[14] O. Almarsson,et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. , 2007, Journal of pharmaceutical sciences.
[15] M. Faul,et al. Salt form selection and characterization of LY333531 mesylate monohydrate. , 2000, International journal of pharmaceutics.
[16] A. Bak,et al. Drug Substance and Former Structure Property Relationships in 15 Diverse Pharmaceutical Co-Crystals , 2009 .
[17] A. Weiner,et al. Controlled Flow-Through Dissolution Methodology: A High-Performance System , 2008 .
[18] Sekhar Surapaneni,et al. The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. , 2008, Journal of pharmaceutical sciences.